amyotrophic lateral sclerosis

[Molecular Neurobiology] Due to paucity of standard protocols in extraction procedures of extracellular vesicles (EVs) and their pharmacological properties and mechanisms, the development of new EV dependent therapies is challenging.

[Nature Neuroscience] Researchers reported the development of a cerebral organoid slice model derived from human induced pluripotent stem cells that recapitulated mature cortical architecture and displayed early molecular pathology of C9ORF72 ALS/FTD.

[Scientific Reports] Scientists used human iPSCs and generated a developmental timeline by differentiating sporadic amyotrophic lateral sclerosis (sALS) iPSCs to neural progenitors and to motor neurons and comparing mitochondrial parameters with familial ALS and control cells at each developmental stage.

[nan] PathMaker Neurosystems, Inc. announced that it was awarded a Phase I STTR grant from NIH’s National Institute of Neurological Disorders and Stroke. The $371,000 award will enable the completion of key pre-clinical studies evaluating the effect of treatment with PathMaker’s breakthrough technology for motor neuron hyperexcitability suppression in transgenic ALS mice.

[Scientific Reports] Researchers presented a transgenic, TDP-43-A315T, mouse model expressing an amyotrophic lateral sclerosis phenotype and demonstrate the presence of ubiquitinated cytoplasmic TDP-43 aggregates with > 80% cell death by 28 days post differentiation in vitro.

[Scientific Reports] Scientists presented a transgenic, TAR DNA-binding protein-43 (TDP-43)-A315T, mouse model expressing an Amyotrophic Lateral Sclerosis (ALS) phenotype and demonstrated the presence of ubiquitinated cytoplasmic TDP-43 aggregates with > 80% cell death by 28 days post differentiation in vitro.